The landscape of T cell antigens for cancer immunotherapy
The remarkable capacity of immunotherapies to induce durable regression in some patients
with metastatic cancer relies heavily on T cell recognition of tumor-presented antigens. As …
with metastatic cancer relies heavily on T cell recognition of tumor-presented antigens. As …
Expanding the therapeutic window for CAR T cell therapy in solid tumors: the knowns and unknowns of CAR T cell biology
K Watanabe, S Kuramitsu, AD Posey Jr… - Frontiers in …, 2018 - frontiersin.org
A major obstacle for chimeric antigen receptor (CAR) T cell therapy in solid tumors is the
lack of truly tumor-specific target antigens, which translates to the targeting of tumor …
lack of truly tumor-specific target antigens, which translates to the targeting of tumor …
NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
AP Rapoport, EA Stadtmauer, GK Binder-Scholl… - Nature medicine, 2015 - nature.com
Despite recent therapeutic advances, multiple myeloma (MM) remains largely incurable.
Here we report results of a phase I/II trial to evaluate the safety and activity of autologous T …
Here we report results of a phase I/II trial to evaluate the safety and activity of autologous T …
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
GP Linette, EA Stadtmauer, MV Maus… - Blood, The Journal …, 2013 - ashpublications.org
An obstacle to cancer immunotherapy has been that the affinity of T-cell receptors (TCRs) for
antigens expressed in tumors is generally low. We initiated clinical testing of engineered T …
antigens expressed in tumors is generally low. We initiated clinical testing of engineered T …
Monoclonal TCR-redirected tumor cell killing
N Liddy, G Bossi, KJ Adams, A Lissina, TM Mahon… - Nature medicine, 2012 - nature.com
T cell immunity can potentially eradicate malignant cells and lead to clinical remission in a
minority of patients with cancer. In the majority of these individuals, however, there is a …
minority of patients with cancer. In the majority of these individuals, however, there is a …
[HTML][HTML] Bispecific T-cell engagers: towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their …
D Ellerman - Methods, 2019 - Elsevier
Bispecific molecules redirecting the cytotoxicity of T-cells are a growing class of therapeutics
with numerous molecules being tested in clinical trials. However, it has been a long way …
with numerous molecules being tested in clinical trials. However, it has been a long way …
Target antigen density governs the efficacy of anti–CD20-CD28-CD3 ζ chimeric antigen receptor–modified effector CD8+ T cells
K Watanabe, S Terakura, AC Martens… - The Journal of …, 2015 - journals.aai.org
The effectiveness of chimeric Ag receptor (CAR)–transduced T (CAR-T) cells has been
attributed to supraphysiological signaling through CARs. Second-and later-generation …
attributed to supraphysiological signaling through CARs. Second-and later-generation …
Bispecific T-cell redirection versus chimeric antigen receptor (CAR)-T cells as approaches to kill cancer cells
WR Strohl, M Naso - Antibodies, 2019 - mdpi.com
The concepts for T-cell redirecting bispecific antibodies (TRBAs) and chimeric antigen
receptor (CAR)-T cells are both at least 30 years old but both platforms are just now coming …
receptor (CAR)-T cells are both at least 30 years old but both platforms are just now coming …
Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions
PF Robbins, YF Li, M El-Gamil, Y Zhao… - The Journal of …, 2008 - journals.aai.org
Single and dual amino acid substitution variants were generated in the TCR CDRs of three
TCRs that recognize tumor-associated Ags. Substitutions that enhance the reactivity of TCR …
TCRs that recognize tumor-associated Ags. Substitutions that enhance the reactivity of TCR …
The quest for the best: how TCR affinity, avidity, and functional avidity affect TCR-engineered T-cell antitumor responses
Over the past decades, adoptive transfer of T cells has revolutionized cancer
immunotherapy. In particular, T-cell receptor (TCR) engineering of T cells has marked …
immunotherapy. In particular, T-cell receptor (TCR) engineering of T cells has marked …